Table 7.
Association between NKG2D haplotypes and genotypes with melanoma.
| NKG2D Haplotypes and Genotypes |
Controls (N = 200) | Melanoma Patients (N = 233) | ||
|---|---|---|---|---|
| Total (N = 191) | SSM (N = 162) | NM (N = 29) | ||
| Hb-1 | ||||
| NK-1 | 163 (81%) | 197 (84%) | 135 (83%) | 26 (90%) |
| NK-2 | 109 (54%) | 110 (47%) | 74 (46%) | 16 (55%) |
| NK-1/NK-1 | 73 (37%) | 92 (40%) | 68 (42%) | 9 (31%) |
| NK-1/NK-2 | 80 (40%) | 84 (36%) | 55 (34%) | 14 (48%) |
| NK-2/NK-2 | 24 (12%) | 20 (9%) | 15 (9%) | 2 (7%) |
| Hb-2 | ||||
| NK-1 | 182 (91%) | 204 (88%) | 139 (86%) | 26 (90%) |
| NK-2 | 84 (42%) | 84 (36%) | 59 (36%) | 11 (38%) |
| NK-1/NK-1 | 106 (53%) | 137 (59%) | 96 (59%) | 15 (52%) |
| NK-1/NK-2 | 65 (33%) | 56 (24%) | 37 (23%) 1 | 8 (28%) |
1 SSM vs. control (p = 0.033; OR = 0.601; 95% CI = 0.375–0.962). Statistical significance was examined by the Χ2 test. ORs were calculated along with 95% CI values.